Wikipedia

User:Mr. Ibrahem/Baricitinib

< User:Mr. Ibrahem
Mr. Ibrahem/Baricitinib
Clinical data
Trade namesOlumiant, others
Other namesINCB28050, LY3009104
AHFS/Drugs.comMonograph
MedlinePlusa618033
License data
Pregnancy
category
  • AU: D[1][2]
  • Use is contraindicated
Routes of
administration		By mouth (tablets)
Drug classJanus kinase inhibitor[3]
Legal status
Legal status
Pharmacokinetic data
Bioavailability79%
Protein binding50%
MetabolismCYP3A4 (<10%)
Elimination half-life12.5 hours
Excretion75% urine, 20% faeces
Identifiers
  • 2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
Chemical and physical data
FormulaC16H17N7O2S
Molar mass371.42 g·mol−1
3D model (JSmol)
  • CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
  • InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
  • Key:XUZMWHLSFXCVMG-UHFFFAOYSA-N

Baricitinib, sold under the brand name Olumiant among others, is a medication used to treat rheumatoid arthritis (RA) and COVID-19.[5][7] In RA it is used in those who are not controlled by tumor necrosis factor (TNF) inhibitors.[5] In COVID-19 it is used in those with severe disease.[7] It is taken by mouth.[6]

Common side effects include nausea, upper respiratory tract infection, shingles, and herpes simplex.[8] Other side effects may include severe infections, lymphoma, blood clots, GI perforation, and liver problems.[8] There is no data one use in pregnancy, though use in other animals may result in harm to the baby.[8] It is an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2.[3]

Baricitinib was approved for medical use in the Europe in 2017 and the United States in 2018.[6][5] In the United Kingdom 28 tablets of 2 mg costs the NHS about £800 as of 2021.[9] This amount in the United States costs about 2,300 USD.[10]

References edit

  1. ^ a b "Olumiant Product Information" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 20 September 2021. Retrieved 12 June 2021.
  2. ^ "Baricitinib (Olumiant) Use During Pregnancy". Drugs.com. 8 November 2019. Archived from the original on 26 June 2020. Retrieved 16 March 2020.
  3. ^ a b "Summary of opinion for Olumiant" (PDF). European Medicines Agency (EMA). 15 December 2016. Archived (PDF) from the original on 15 March 2018. Retrieved 1 September 2021.
  4. ^ "AusPAR: Baricitinib". Therapeutic Goods Administration (TGA). 20 May 2021. Archived from the original on 20 May 2021. Retrieved 11 June 2021.
  5. ^ a b c d e "Olumiant- baricitinib tablet, film coated". DailyMed. 13 November 2019. Archived from the original on 27 September 2020. Retrieved 16 March 2020.
  6. ^ a b c "Olumiant EPAR". European Medicines Agency (EMA). 3 December 2019. Archived from the original on 25 August 2021. Retrieved 1 September 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  7. ^ a b c "Hospitalized Adults: Therapeutic Management". COVID-19 Treatment Guidelines. Archived from the original on 9 January 2022. Retrieved 8 January 2022.
  8. ^ a b c d "Baricitinib Monograph for Professionals". Drugs.com. Archived from the original on 21 September 2021. Retrieved 8 January 2022.
  9. ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1153. ISBN 978-0857114105.
  10. ^ "Olumiant Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 22 January 2021. Retrieved 8 January 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Baricitinib&oldid=1166658674"